Description
SWOT ANALYSIS OF AUROBINDO PHARMA
Aurobindo Pharma
Parent Company
Aurobindo Pharma
Category
Pharmaceutical
Sector
Health care
Tagline/ Slogan
Committed to healthier life!
Among the largest 'Vertically Integrated' pharmaceutical companies in USP India, with a robust product portfolio
STP
CVS, Antibiotics, Gastroenterologicals, Anti-Diabetics , Anti-Allergic Segment Anti-Retroviral and CNS
Target Group
Patients and doctors who seek good health
They are global pharmaceutical company with great commitment to Positioning healthier life
SWOT Analysis
1. A new drug Nevirapine discovered against the HIV infective disease has been approved by the US FDA, which will increase the market size and profits of the company. 2. Approval of generic version of Clopidogrel from FDA will boost revenue of company 3. A greater growth in terms of sales in the US and Europe due to various US approvals 4. Strong marketing network Strength 5. Aurobindo exports to over 125 countries across the globe
1. Retirement of the three top most directors will have an impact on the functioning till new capable people join. 2. The company is not into mergers or acquisitions which will help it increase the product list 3. Very low in the corporate social front Weakness 4. Largely dependant on Indian market for revenue generation
1. Increasing health awareness 2. improving the R&D section to expand the product pipeline 3. Globalize and further break through into joint ventures and Opportunity subsidiaries into China, Brazil and other Latin American markets.
1. The European crisis, which will have a great impact on the sales since major orders are from the Europe and US 2. Depreciating value of currency will affect the export Threats 3. Peers post a major competition.
Competition
1. Cipla 2. Dr.Reddy's Laboratories 3. Sun Pharma Industries Competitors 4. Ranbaxy
doc_654868179.docx
SWOT ANALYSIS OF AUROBINDO PHARMA
Aurobindo Pharma
Parent Company
Aurobindo Pharma
Category
Pharmaceutical
Sector
Health care
Tagline/ Slogan
Committed to healthier life!
Among the largest 'Vertically Integrated' pharmaceutical companies in USP India, with a robust product portfolio
STP
CVS, Antibiotics, Gastroenterologicals, Anti-Diabetics , Anti-Allergic Segment Anti-Retroviral and CNS
Target Group
Patients and doctors who seek good health
They are global pharmaceutical company with great commitment to Positioning healthier life
SWOT Analysis
1. A new drug Nevirapine discovered against the HIV infective disease has been approved by the US FDA, which will increase the market size and profits of the company. 2. Approval of generic version of Clopidogrel from FDA will boost revenue of company 3. A greater growth in terms of sales in the US and Europe due to various US approvals 4. Strong marketing network Strength 5. Aurobindo exports to over 125 countries across the globe
1. Retirement of the three top most directors will have an impact on the functioning till new capable people join. 2. The company is not into mergers or acquisitions which will help it increase the product list 3. Very low in the corporate social front Weakness 4. Largely dependant on Indian market for revenue generation
1. Increasing health awareness 2. improving the R&D section to expand the product pipeline 3. Globalize and further break through into joint ventures and Opportunity subsidiaries into China, Brazil and other Latin American markets.
1. The European crisis, which will have a great impact on the sales since major orders are from the Europe and US 2. Depreciating value of currency will affect the export Threats 3. Peers post a major competition.
Competition
1. Cipla 2. Dr.Reddy's Laboratories 3. Sun Pharma Industries Competitors 4. Ranbaxy
doc_654868179.docx